There are several studies investigating SGLT2 inhibitors in NAFLD that are actively recruiting (https://clinicaltrials.gov/ct2/home), although all are exclusively on patients with T2D. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.